[go: up one dir, main page]

HUP0302160A2 - GABA agonisták és szorbitol dehidrogenáz inhibitorok kombinációját tartalmazó gyógyszerkészítmények - Google Patents

GABA agonisták és szorbitol dehidrogenáz inhibitorok kombinációját tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0302160A2
HUP0302160A2 HU0302160A HUP0302160A HUP0302160A2 HU P0302160 A2 HUP0302160 A2 HU P0302160A2 HU 0302160 A HU0302160 A HU 0302160A HU P0302160 A HUP0302160 A HU P0302160A HU P0302160 A2 HUP0302160 A2 HU P0302160A2
Authority
HU
Hungary
Prior art keywords
prodrug
sorbitol dehydrogenase
combination
pharmaceutical compositions
compositions containing
Prior art date
Application number
HU0302160A
Other languages
English (en)
Inventor
Banavara Lakshman Mylari
Original Assignee
Pfizer Products Inc.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc., filed Critical Pfizer Products Inc.,
Publication of HUP0302160A2 publication Critical patent/HUP0302160A2/hu
Publication of HUP0302160A3 publication Critical patent/HUP0302160A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A jelen találmány tárgyát képezik a g-amino-butirsav (GABA), annakelőgyógyszere vagy az említett GABA-agonista vagy annak előgyógyszeregyógyszerészetileg elfogadható sója és szorbitot dehidrogenázinhibitor (SDI) vegyület, annak előgyógyszere vagy az említett SDI-vegyület és előgyógyszere gyógyszerészetileg elfogadható sója általalkotott gyógyszerkészítmények, a kombinációkat tartalmazó kitek,valamint ezeknek a kombinációknak a felhasználási eljárásai olyanemlősök, ideértve az embert is, kezelésére, amelyek olyancukorbetegséggel együttjáró szövődményektől szenvednek többek között,mint a cukorbetegséggel együttjáró idegbántalom, a vesebetegség, aszívizom betegség, a szemideghártya bántalom, a kis erek bántalma, anagy erek betegsége, a szürkehályog vagy a lábszárfekélyek. Ó
HU0302160A 2000-11-30 2001-11-19 Pharmaceutical compositions containing the combination of gaba agonists and sorbitol dehydrogenase inhibitors HUP0302160A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25006900P 2000-11-30 2000-11-30
PCT/IB2001/002213 WO2002043762A2 (en) 2000-11-30 2001-11-19 Combination of gaba agonists and sorbitol dehydrogenase inhibitors

Publications (2)

Publication Number Publication Date
HUP0302160A2 true HUP0302160A2 (hu) 2003-11-28
HUP0302160A3 HUP0302160A3 (en) 2005-05-30

Family

ID=22946187

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302160A HUP0302160A3 (en) 2000-11-30 2001-11-19 Pharmaceutical compositions containing the combination of gaba agonists and sorbitol dehydrogenase inhibitors

Country Status (38)

Country Link
US (1) US6544998B2 (hu)
EP (1) EP1337271B1 (hu)
JP (1) JP2004514699A (hu)
KR (1) KR20030059290A (hu)
CN (1) CN1477975A (hu)
AP (1) AP2001002360A0 (hu)
AR (1) AR031431A1 (hu)
AT (1) ATE281181T1 (hu)
AU (1) AU2002215159A1 (hu)
BG (1) BG107774A (hu)
BR (1) BR0115783A (hu)
CA (1) CA2430298A1 (hu)
CR (1) CR6964A (hu)
CZ (1) CZ20031399A3 (hu)
DE (1) DE60106968T2 (hu)
DO (1) DOP2001000289A (hu)
EA (1) EA200300432A1 (hu)
EC (1) ECSP034624A (hu)
EE (1) EE200300248A (hu)
ES (1) ES2230378T3 (hu)
HR (1) HRP20030420A2 (hu)
HU (1) HUP0302160A3 (hu)
IL (1) IL155704A0 (hu)
IS (1) IS6786A (hu)
MA (1) MA26964A1 (hu)
MX (1) MXPA03004870A (hu)
NO (1) NO20032441L (hu)
OA (1) OA12534A (hu)
PA (1) PA8534101A1 (hu)
PE (1) PE20020597A1 (hu)
PL (1) PL365927A1 (hu)
PT (1) PT1337271E (hu)
SK (1) SK6192003A3 (hu)
SV (1) SV2003000751A (hu)
TN (1) TNSN01169A1 (hu)
UY (1) UY27042A1 (hu)
WO (1) WO2002043762A2 (hu)
ZA (1) ZA200303381B (hu)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU714980B2 (en) 1996-07-24 2000-01-13 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
US6992109B1 (en) * 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
US7022678B2 (en) * 2001-03-30 2006-04-04 Warner-Lambert Company Pregabalin lactose conjugates
CZ299755B6 (cs) * 2001-05-25 2008-11-12 Warner-Lambert Company Llc Kapalná farmaceutická kompozice obsahující analoggama-aminomáselné kyseliny, zpusob její prípravy a použití
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
KR20050036195A (ko) * 2003-10-15 2005-04-20 고재영 신규한 망막병증 치료제 조성물
US20050220873A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
EP1729740A2 (en) * 2004-04-02 2006-12-13 Impax Laboratories, Inc. PHARMACEUTICAL DOSAGE FORMS HAVING IMMEDIATE RELEASE AND/OR CONTROLLED RELEASE PROPERTIES THAT CONTAIN A GABA<SB>B</SB> RECEPTOR AGONIST
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
KR101063663B1 (ko) 2005-02-17 2011-09-07 아스텔라스세이야쿠 가부시키가이샤 피리딜 비방향족 질소 함유 헤테로환-1-카르복실산에스테르유도체
GB0513553D0 (en) * 2005-07-01 2005-08-10 Fond D Amico Per La Ricerca Su Rab3a
MY148657A (en) 2007-04-27 2013-05-15 Purdue Pharma Lp Trpv1 antagonists and uses thereof
AU2008310114B2 (en) * 2007-10-09 2014-01-16 Merck Patent Gmbh Pharmaceutical compositions containing benfotiamine and one or more pharmaceutically active agents for the treatment of pain conditions of neuropathic origin
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
CN103228142A (zh) * 2010-09-28 2013-07-31 加利福尼亚大学董事会 治疗代谢综合征相关疾病的gaba激动剂和治疗或预防i型糖尿病的gaba组合
ES2620528T3 (es) 2011-06-22 2017-06-28 Purdue Pharma Lp Antagonistas de TRPV1 que incluyen un sustituyente dihidroxi y usos de los mismos
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US20220169668A1 (en) 2019-04-17 2022-06-02 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
MX2021013511A (es) * 2019-05-07 2022-02-23 Univ Miami Tratamiento y deteccion de neuropatias heredadas y trastornos asociados.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2409754A (en) 1946-10-22 Method for obtaining hydantoins
CH449645A (de) 1963-07-09 1968-01-15 Ciba Geigy Verfahren zur Herstellung neuer Aminosäuren
CH427803A (de) 1963-12-06 1967-01-15 Geigy Ag J R Verfahren zur Herstellung eines neuen Isoxazolderivates
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US3960927A (en) 1975-03-18 1976-06-01 Richardson-Merrell Inc. Olefinic derivatives of amino acids
FR2319338A1 (fr) * 1975-08-01 1977-02-25 Synthelabo Nouveaux derives de a- phenyl benzylideniques des acides amines, leur preparation et les medicaments qui en contiennent
EP0059987B1 (en) 1979-06-01 1985-08-14 The Wellcome Foundation Limited Alpha-cyano-alpha-((n-guanidino)-imino) toluenes
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
DK288385D0 (da) 1985-06-26 1985-06-26 Novo Industri As Aminosyrederivater
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
CA2145640C (en) * 1992-09-28 2001-01-30 Banavara L. Mylari Substituted pyrimidines for control of diabetic complications
US6350769B1 (en) * 1999-02-24 2002-02-26 The Regents Of The University Of California Gaba alpha receptors mediate inhibition of T cell responses
ES2215570T3 (es) * 1999-04-01 2004-10-16 Pfizer Products Inc. Compuestos para tratar y prevenir complicaciones diabeticas.
TR200102810T2 (tr) * 1999-04-01 2002-01-21 Pfizer Products Inc. Sorbitol dehidrojenaz inhibitörleri olarak aminopirimidinler

Also Published As

Publication number Publication date
SK6192003A3 (en) 2004-07-07
JP2004514699A (ja) 2004-05-20
AR031431A1 (es) 2003-09-24
IL155704A0 (en) 2003-11-23
PT1337271E (pt) 2005-01-31
ES2230378T3 (es) 2005-05-01
UY27042A1 (es) 2002-07-31
EE200300248A (et) 2003-10-15
MXPA03004870A (es) 2003-08-19
PA8534101A1 (es) 2002-10-31
WO2002043762A2 (en) 2002-06-06
DE60106968D1 (de) 2004-12-09
TNSN01169A1 (fr) 2005-11-10
CZ20031399A3 (cs) 2004-04-14
US6544998B2 (en) 2003-04-08
PL365927A1 (en) 2005-01-10
ATE281181T1 (de) 2004-11-15
PE20020597A1 (es) 2002-07-08
US20020091128A1 (en) 2002-07-11
KR20030059290A (ko) 2003-07-07
ECSP034624A (es) 2003-07-25
ZA200303381B (en) 2004-04-30
CN1477975A (zh) 2004-02-25
SV2003000751A (es) 2003-01-13
BR0115783A (pt) 2003-09-16
AP2001002360A0 (en) 2001-12-31
NO20032441D0 (no) 2003-05-28
OA12534A (en) 2006-06-05
IS6786A (is) 2003-04-14
HUP0302160A3 (en) 2005-05-30
BG107774A (en) 2004-01-30
AU2002215159A1 (en) 2002-06-11
WO2002043762A3 (en) 2003-03-13
MA26964A1 (fr) 2004-12-20
DOP2001000289A (es) 2003-02-15
NO20032441L (no) 2003-07-03
EP1337271B1 (en) 2004-11-03
HRP20030420A2 (en) 2004-08-31
CA2430298A1 (en) 2002-06-06
CR6964A (es) 2004-02-02
EA200300432A1 (ru) 2003-10-30
EP1337271A2 (en) 2003-08-27
DE60106968T2 (de) 2005-11-03

Similar Documents

Publication Publication Date Title
HUP0302160A2 (hu) GABA agonisták és szorbitol dehidrogenáz inhibitorok kombinációját tartalmazó gyógyszerkészítmények
Milne et al. Isoprostane generation and function
EA200501936A1 (ru) Производные пиридо[2,1-a]изохинолина в качестве ингибиторов dpp-iv
DK1814534T3 (da) Derivater af 5-aminolevulinsyre til behandling af acne
MA26946A1 (fr) Derives de pyrazole nouveaux et leur utilisation comme inhibiteurs de proteine-kinases.
BRPI0416628A (pt) uso de compostos orgánicos
CY1108823T1 (el) Παραγωγα 2-υδροξυ-3-ετεροαρυλινδολης ως αναστολεις της gsk3
IS2734B (is) Pýrasólafleiður og notkun þar á, ásamt lyfjasamsetningum
BR0211119A (pt) Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto
HUP0001286A2 (hu) Karbazol-ecetsavat tartalmazó, kutyák fájdalmának és gyulladásának kezelésére alkalmas gyógyszerkészítmény
CN110430876A (zh) 用于组合疗法的药物组合物
EA200500376A1 (ru) Триазольные производные в качестве ингибиторов трансформирующего фактора роста (tgf)
NO20054958L (no) Substitulerte aminokarboksylsyrer
RU2007142328A (ru) Производные тиоксантина в качестве ингибиторов миелопероксидазы
TW200735874A (en) Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
BRPI0617655A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica
ATE305777T1 (de) Mittel zur verhinderung der chronischen abstossreaktion infolge einer organtransplantation
EA200801308A1 (ru) Комбинации, включающие ингибитор cdk и антитело фактора роста, или антимитотик
EP2809317A1 (en) Fatty acids as anti-inflammatory agents
WO2003048122A3 (en) Inhibitors of cytosolic phospholipase a2
BR0210392A (pt) Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
NO20071098L (no) Quinazolinderivater som er nyttige ved behandling av perifer arteriesykdom og som fosfodiesterase-inhibitorer
Benyahia et al. Ex vivo relaxations of pulmonary arteries induced by prostacyclin mimetics are highly dependent of the precontractile agents
JP2002105067A (ja) ２−フェニルチアゾール誘導体、およびそれを有効成分とする医薬組成物
NO20051011L (no) Kirale oksazol-arylpropionsyrederivater og anvendelse derav som PPAR agonister